U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07449923) titled 'CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME' on Feb. 27.
Brief Summary: This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Study Start Date: Feb. 09
Study Type: INTERVENTIONAL
Condition:
Diabetic Macular Edema
DME
Diabetic Macular Edema (DME)
Intervention:
DRUG: EYP-1901
Intravitreal Injection
DRUG: Aflibercept (2.0 mg)
Intravitreal Injection
Recruitment Status: RECRUITING
Sponsor: EyePoint Pharmaceuticals, Inc.
Disclaimer: Curated by HT Syndication....